Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
15 May 24
S-1
IPO registration
10 May 24
D
$3.00 mm in equity, sold $3.00 mm, 19 investors
30 Apr 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
Carmell Announces $3.0 Million Private Placement
4 Apr 24
8-K
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Entry into a Material Definitive Agreement
25 Mar 24
8-K
Carmell Corp Announces Addition of Dr. Bradley Calobrace to Scientific Advisory Board
16 Jan 24
8-K
Carmell Corp Announces Addition of Dr. Sean Kelishadi to Scientific Advisory Board
16 Jan 24
8-K
Carmell Corp Announces Addition of Dr. Gregory A. Buford to Scientific Advisory Board
16 Jan 24
8-K/A
Carmell Corp Announces Addition of Dr. Adam Rubinstein to Scientific Advisory Board
16 Jan 24
8-K/A
Carmell Corp Announces Addition of Dr. Jason D. Bloom to Scientific Advisory Board
16 Jan 24
8-K
Carmell Corp Announces Addition of Dr. Adam Rubinstein to Scientific Advisory Board
16 Jan 24
8-K
Carmell Corp Announces Addition of Dr. Jason D. Bloom to Scientific Advisory Board
16 Jan 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors
15 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K/A
Unaudited Condensed Financial Statements
25 Oct 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
8-K/A
Completion of Acquisition or Disposition of Assets
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity
14 Aug 23
S-1
IPO registration
7 Aug 23
8-K
Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
1 Aug 23
8-K
Entry into a Material Definitive Agreement
20 Jul 23
25-NSE
Exchange delisting
14 Jul 23
8-K
Other Events
14 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
12 Jul 23
425
Business combination disclosure
10 Jul 23
8-K
Entry into a Material Definitive Agreement
10 Jul 23
425
Business combination disclosure
6 Jul 23
8-K
Other Events
6 Jul 23
425
Business combination disclosure
27 Jun 23
8-K
Other Events
27 Jun 23
EFFECT
Notice of effectiveness
26 Jun 23
424B3
Prospectus supplement
23 Jun 23
CORRESP
Correspondence with SEC
22 Jun 23
Latest ownership filings
4
Rajiv Shukla
22 May 24
4
Rajiv Shukla
22 May 24
SC 13G/A
SANDSTONE Asset Management
18 Apr 24
SC 13G/A
P SCHOENFELD ASSET MANAGEMENT LP
14 Feb 24
SC 13G/A
Antara Capital LP
14 Feb 24
SC 13G
METEORA CAPITAL, LLC
14 Feb 24
SC 13G/A
BALYASNY ASSET MANAGEMENT L.P.
14 Feb 24
SC 13G/A
Sculptor Capital LP
14 Feb 24
SC 13G/A
UBS OCONNOR LLC
12 Feb 24
SC 13G/A
Linden Capital L.P.
7 Feb 24
SC 13G
Newlin Investment Co 1, LLC
6 Feb 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
5 Feb 24
4
Rajiv Shukla
4 Jan 24
4
Bryan J. Cassaday
19 Dec 23
4
Gilles Spenlehauer
18 Dec 23
4
Scott M. Frisch
18 Dec 23
4
Patrick A Sturgeon
18 Dec 23
4
Kathryn Gregory
18 Dec 23
4
David W Anderson
18 Dec 23
4
Richard A Upton
13 Dec 23
4
Patrick A Sturgeon
13 Dec 23
4
Scott M. Frisch
13 Dec 23
4
Gilles Spenlehauer
13 Dec 23
4
Kathryn Gregory
13 Dec 23
4
David W Anderson
13 Dec 23
4
David W Anderson
8 Dec 23
4
Patrick A Sturgeon
8 Dec 23
4
Kathryn Gregory
8 Dec 23
4
Gilles Spenlehauer
8 Dec 23
4
Scott M. Frisch
8 Dec 23
3
Scott M. Frisch
8 Dec 23
3
Gilles Spenlehauer
8 Dec 23
3
Bryan J. Cassaday
8 Dec 23
4
Rajiv Shukla
4 Dec 23
4
Bryan J. Cassaday
30 Nov 23
4
Rajiv Shukla
28 Nov 23
4
Rajiv Shukla
21 Nov 23
SC 13G
Shukla Rajiv
21 Nov 23
4
Rajiv Shukla
31 Aug 23
4
Randolph W Hubbell
30 Aug 23